Targeting the p53–MDM2 interaction to treat cancer
Open Access
- 28 September 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 91 (8), 1415-1419
- https://doi.org/10.1038/sj.bjc.6602164
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Burkholderia Hep_Hag autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosisBMC Microbiology, 2007
- Pfam: clans, web tools and servicesNucleic Acids Research, 2006
- Binding of Escherichia coli Hemolysin and Activation of the Target Cells Is Not Receptor-dependentPublished by Elsevier BV ,2005
- Evidence in the Legionella pneumophila genome for exploitation of host cell functions and high genome plasticityNature Genetics, 2004
- MDM2 Is a Negative Regulator of p21 , Independent of p53Published by Elsevier BV ,2004
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in VivoPublished by Elsevier BV ,2002
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000
- Improved microbial gene identification with GLIMMERNucleic Acids Research, 1999